Biologics
eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing
eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, throug...
November 27, 2025 | News
Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...
November 26, 2025 | News
Innova Therapeutics Acquires Enci Therapeutics To Advance First in Class SFRP2 Antibody IVT8086 for Solid and Haematological Cancers
The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is exp...
November 26, 2025 | News
BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
BioMed X, a leading external innovation hub for pharma, announced the launch of a new collaborative research project with AbbVie, hosted at the BioMed...
November 26, 2025 | News
Harbour BioMed Deepens Global Collaboration with AstraZeneca to Advance Next Generation Biotherapeutics
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...
November 25, 2025 | News
ToolGen and GenEditBio Join Forces to Advance Next Generation In Vivo Genome Editing
Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology Pursues a "once-...
November 25, 2025 | News
ACG Introduces DryPod The New Lamination Based Desiccant Cold Form Solution That Gives Drug Makers Full Control Over Moisture Protection
ACG, the world’s most integrated provider of solid-dosage and packaging solutions, announced the launch of DryPod™, a next-generatio...
November 24, 2025 | News
Pfizer and Astellas Gain Landmark FDA Approval for PADCEV and Keytruda in Cisplatin Ineligible Muscle Invasive Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can significantly improve survival over current standard of ca...
November 24, 2025 | News
China Marks a Landmark Moment as BioDlink and Lepu Biopharma Launch the World’s First EGFR Targeting ADC
Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their par...
November 24, 2025 | News
Global Leaders Signal a Confident New Chapter for Cell and Gene Therapy at GenScript Global Forum London 2025
GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum ...
November 24, 2025 | News
ReviR Therapeutics Wins CIRM Grant to Advance First in Class Dual Target Therapy for Huntington’s Disease
ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced that it has been awarded a $4....
November 21, 2025 | News
Tsingke Biotech Showcases Breakthrough Speed in Protein and Antibody Development at PEGS Europe 2025
At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest ac...
November 20, 2025 | News
YolTech Therapeutics Receives FDA Clearance to Begin Pivotal Trial for In Vivo Gene Editing Therapy in PH1
YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food ...
November 20, 2025 | News
AGC Biologics and Repair Biotechnologies Partner to Advance a Novel mRNA Therapy for Atherosclerotic Disease
Partnership leverages AGC Biologics’ cost-effective and dependable cGMP mRNA and LNP capabilities AGC Biologics announced it is partnering w...
November 20, 2025 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
